SCHEMBL2097995

SCHEMBL2097995

CCOC(=O)Nc1ccc(F)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.70
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
CASP3 P42574 1/20 0.64
TRPV1 Q8NER1 1/20 0.64
SENP7 Q9BQF6 1/20 0.64
SMN1; SMN2 Q16637 5/20 0.63
NPC1 O15118 3/20 0.63
RAB9A P51151 3/20 0.63
KDM4E B2RXH2 2/20 0.63
HPGD P15428 2/20 0.61
CRHBP P24387 1/20 0.61
CRHR2 Q13324 1/20 0.61
TSHR P16473 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.57
GAA P10253 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MTNR1B P49286 1/20 0.56
KCNQ3 O43525 1/20 0.56
KCNQ2 O43526 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7565510 0.90 RAB9A (0.71) MAPTSMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL15996898 0.88 KCNQ3 (0.70) MAPTMEN1KMT2ACASP3TRPV1
SCHEMBL19938056 0.86 SMN1; SMN2 (0.67) MAPTMEN1KMT2ACASP3TRPV1
SCHEMBL1577955 0.85 MEN1 (0.59) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL9146676 0.85 LMNA (0.68) MAPTSMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL7565512 0.85 RAB9A (0.70) MAPTSMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL1719720 0.85 SMN1; SMN2 (0.71) MAPTSMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL11790359 0.85 RAB9A (0.65) MAPTSMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL3826853 0.84 RAB9A (0.52) MAPTCASP3SENP7SMN1; SMN2NPC1
SCHEMBL352811 0.83 RAB9A (0.63) MAPTMEN1KMT2ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3508473-B1 METHOD FOR PRODUCING CARBAMIC ACID ESTER AIST (JP) 2021-05-26 EP disclosed
US-10752579-B2 Production method of carbamic acid ester NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2020-08-25 US disclosed
EP-3508473-A1 METHOD FOR PRODUCING CARBAMIC ACID ESTER National Institute of Advanced Industrial Science and Technology (JP) 2019-07-10 EP disclosed
US-20190185420-A1 PRODUCTION METHOD OF CARBAMIC ACID ESTER NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2019-06-20 US disclosed
US-8569267-B2 Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain JANSSEN PHARMACEUTICA, NV (BE) 2013-10-29 US disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-4973697-A 2-halopyridine-6-sulfonic acid and its salt ONODA CEMENT CO., LTD. (JP) 1990-11-27 US disclosed
EP-0393462-A2 2-halopyridine-6-sulfonic acid and its salt ONODA CEMENT COMPANY, LTD. (JP) 1990-10-24 EP disclosed
EP-0341019-A2 Polyether antibiotic ELI LILLY AND COMPANY (US) 1989-11-08 EP disclosed
US-4683201-A Antibiotic A80190-producing Actinomadura oligospora and process ELI LILLY AND COMPANY (US) 1987-07-28 US disclosed
US-4634704-A HISTAMINE AND SEROTONINE ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 1987-01-06 US disclosed
CN-85108210-A Preparation A80190 antibiotic method 1986-12-03 CN disclosed
EP-0184291-A2 Polyether antibiotic A80190 ELI LILLY AND COMPANY (US) 1986-06-11 EP disclosed
US-4582822-A ANIMAL FEED ADDITIVES ELI LILLY AND COMPANY (US) 1986-04-15 US disclosed
US-4294925-A FERMENTATION, AEROBIC PROCESSES HOFFMANN-LA ROCHE INC. (US) 1981-10-13 US disclosed
US-4263427-A REACTING HYDROXYL WITH ISOCYANATE TO OBTAIN ANTIBIOTICS HOFFMANN-LA ROCHE INC. (US) 1981-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain HTR2C, HTR2A, HTR5A MAPT 3030/4885MEN1 4320/4885KMT2A 1892/4885
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MAPT 4299/4885MEN1 4525/4885KMT2A 3324/4885
US-20190185420-A1 PRODUCTION METHOD OF CARBAMIC ACID ESTER CA2, CA7, CA4 MAPT 2148/4885MEN1 2437/4885KMT2A 243/4885
US-10752579-B2 Production method of carbamic acid ester CA2, CA7, CA4 MAPT 2148/4885MEN1 2437/4885KMT2A 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.